Fulgent Genetics Q3 revenue rises 8% on improved collection rates
Fulgent Genetics Q3 revenue rises 8% on improved collection rates
Overview
Genetic testing firm's Q3 revenue rose 8% yr/yr
Company posted Q3 non-GAAP net loss of $2.4 mln
Company maintained annual revenue guidance and improved non-GAAP loss outlook
Outlook
Fulgent maintains 2026 revenue guidance of $330 mln to $340 mln
Company now expects 2026 non-GAAP loss of $46 mln to $50 mln
Fulgent expects 2026 non-GAAP loss per share of $1.65 to $1.75
Result Drivers
COLLECTION RATES - Co said improved collection rates and progress in addressing billing system issues supported Q3 results, per CFO Paul Kim
AI INTEGRATION - Co said ongoing integration of AI in laboratory services is improving efficiency and reliability, per CEO Ming Hsieh
THERAPEUTICS PIPELINE - Co cited momentum in therapeutics pipeline, including FID-007 and FID-022, as a positive factor, per CEO Ming Hsieh
Company press release: ID:nBwyVgtba
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $90.41 mln | $86.30 mln (1 Analyst) |
Q3 Adjusted EBITDA |
| -$7.5 mln | -$20 mln (1 Analyst) |
Q3 Gross Profit |
| $31.95 mln |
|
Q3 Operating Expenses |
| $54.49 mln |
|
Q3 Operating Income |
| -$22.55 mln |
|
Q3 Pretax Loss |
| $14.04 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "hold"
The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for Fulgent Genetics, Inc. is $19.00, about 3.5% below its November 4 closing price of $19.68
Reuters Recommended Reads
Nov 4 - Myriad Genetics Q3 revenue beats analyst estimates, raises FY guidance
Nov 4 - Caris Life Sciences' Q3 revenue rises on molecular profiling strength
Nov 3 - SOPHiA GENETICS Q3 revenue rises on US market strength
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Fulgent Genetics
See all newsFulgent Genetics, Inc. reports results for the quarter ended September 30 - Earnings Summary
Fulgent Genetics Q3 revenue rises 8% on improved collection rates
Brief: Fulgent Genetics Q3 Revenue USD 90.412 Million
U.S. RESEARCH ROUNDUP-Cloudflare, Replimune, Walmart
Fulgent Genetics Inc reports results for the quarter ended June 30 - Earnings Summary